Disease Info Download
MedlinePlus is an online health information resource for patients and their families and friends. It is a service of the National Library of Medicine (NLM), the world's largest medical library, which is part of the National Institutes of Health (NIH).Learn more about MedlinePlus
Disease Info download
The Genetic and Rare Diseases (GARD) Information Center is a public health resource for people living with a rare disease and their families. It provides free access to reliable, easy-to-understand information in English and Spanish.
GARD information specialists are available by phone and email to discuss questions in English and Spanish. Sources of information on GARD include the National Library of Medicine, Orphanet, Human Phenotype Ontology, patient support groups and other NIH Institutes and Centers.
Any medical information provided is solely for the purpose of providing information and is not intended as medical advice. You should always talk to your personal healthcare providers for specific medical and health-related instructions and guidelines.
NIMH supports a wide range of research, including clinical trials that look at new ways to prevent, detect, or treat diseases and conditions, including eating disorders. Although individuals may benefit from being part of a clinical trial, participants should be aware that the primary purpose of a clinical trial is to gain new scientific knowledge so that others may be better helped in the future.
Researchers at NIMH and around the country conduct clinical trials with patients and healthy volunteers. Talk to your health care provider about clinical trials, their benefits and risks, and whether one is right for you. For more information about clinical research and how to find clinical trials being conducted around the country, visit NIMH's clinical trials webpage.
The Third Edition of the GIRD Report from FIRS is now available online. This report aims to raise awareness regarding the prevention, diagnosis, treatment, and elimination of respiratory diseases worldwide.
I understand that The Ohio State University Wexner Medical Center provides this instrument and accompanying interpretive guidelines (collectively the "Instrument") as an informational service. Use of the Instrument is governed by the terms and conditions. Please read the statements carefully before accessing or using the Instrument. By accessing or using the Instrument, you agree to be bound by all the terms and conditions herein.
The Instrument is provided AS IS, WITHOUT REPRESENTATION AS TO ITS FITNESS FOR ANY PURPOSE, AND WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. No guarantees are made with respect to accuracy, completeness, errors, or omissions of content. The Ohio State University has no obligation to provide support, updates, enhancements, or other modifications. In no event will the Ohio State University be liable for any decision made or action taken in reliance upon the information provided through the Instrument. THE OHIO STATE UNIVERSITY SHALL NOT BE LIABLE FOR ANY COMPENSATORY OR NON-COMPENSATORY DAMAGES, INCLUDING BUT NOT LIMITED TO SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, WITH RESPECT TO ANY CLAIM ARISING OUT OF OR IN CONNECTION WITH THE USE OF THE INSTRUMENT, EVEN IF IT HAS BEEN OR IS HEREAFTER ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
You may want to take SAGE if you are concerned that you might have cognitive issues. Or you may wish to have your family or friends take the test if they are having memory or thinking problems. The difficulties listed can be early signs of cognitive and brain dysfunction. While dementia or Alzheimer's disease can lead to these symptoms, there are many other treatable disorders that also may cause these signs.
Remember that SAGE does not diagnose any specific condition. The results of SAGE will not tell you if you have Alzheimer's disease, mini-strokes or any number of other disorders. But the results can help your doctor know if further evaluation is necessary.
Examinees who download SAGE from the Internet and take it at home are instructed to bring their completed test to their primary care physician. Scoring instructions and explanations for physicians are below:
Our Medical Information team of dedicated pharmacists, physicians, and associates creates the essential clinical content for epocrates. Our team strives to provide information that is objective, accurate, current, concise, and clinically relevant.Learn how we develop our drug content
Our Medical Information team of dedicated pharmacists, physicians, and associates creates the essential clinical content for epocrates. Our team strives to provide information that is objective, accurate, current, concise, and clinically relevant.\r\n\r\nLearn how we develop our drug content
You can download the European Medicines Agency's (EMA) medicine-related data published on this website in Excel table format from this page. EMA updates these medicine data tables once a day.
European public assessment reports (EPARs) are full scientific assessment reports of medicines authorised at a European Union level. EPARs also contain a public-friendly overview in question-and-answer format and the package leaflet. You can also find information on medicines that have been refused a marketing authorisation or that have been suspended or withdrawn after being approved.
An orphan designation allows a pharmaceutical company to benefit from incentives from the European Union to develop a medicine for a rare disease, such as reduced fees and protection from competition once the medicine is placed on the market. Applications for orphan designation are examined by EMA's Committee for Orphan Medicinal Products (COMP), which adopts an opinion that is forwarded to the European Commission. The European Commission then decides whether to grant an orphan designation for the medicine in question.
EMA's scientific committees (PRAC and CHMP) and the CMDh together with the lead Member State assess the information in the related PSURs to determine whether the balance of benefits and risks has changed and whether any updates should be made to the marketing authorisation.
Documents presenting 'CMDh scientific conclusions and grounds for the variation, amendments to the product information and timetable for the implementation' contain all language versions within a single PDF file if they were published before 17 October 2016.
EMA assesses medicine shortages that affect or are likely to affect more than one EU Member State. Following its assessment, EMA publishes information on specific shortages and provided recommendations to patients and healthcare professionals across the EU.
Please do not include any personal data, such as your name or contact details. If you want to ask a question or request information from EMA, please Send a question to the European Medicines Agency.
Find here all the materials you need to raise awareness and instigate change for people living with a rare disease. Social media posts, posters, infopacks, tool kits, fact sheets, infographics and more.
Shareable infographics with key rare disease statistics, available in two sizes (square 1080x1080 and landscape 1920x1080). Landscape cards also available in 7 languages: English, Arabic, French, Spanish, Portuguese, Hindi, Chinese. Translations for square cards are coming soon.
At the request of Member States, data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country will be available to download from 11 March 2021. ECDC will continue to publish weekly updates on the number of cases and deaths reported in the EU/EEA and worldwide every Thursday. The daily and weekly data are available as downloadable files in the following formats: XLSX, CSV, JSON and XML.
We've put together a COVID-19 Information Dashboard, to provide a comprehensive summary of relevant COVID-19 research, in an effort to help researchers find the information they need quickly and effectively.
With more than 1,200 rare disorders, you can explore rare disease reports that include information on symptoms, causes, treatments, clinical trials, and sources of help such as patient advocacy organizations. Each report has a list of references, such as textbooks, articles, and government agency reports.
A rare disorder is a disease or condition that affects fewer than 200,000 Americans. Cumulatively, there are more than 7,000 rare diseases affecting more than 30 million Americans. NORD is committed to the identification, treatment, and cure of rare diseases through education, advocacy, research, and service programs.
NORD is a registered 501(c)(3) charity organization.Please note that NORD provides this information for the benefit of the rare disease community. NORD is not a medical provider or health care facility and thus can neither diagnose any disease or disorder nor endorse or recommend any specific medical treatments. Patients must rely on the personal and individualized medical advice of their qualified health care professionals before seeking any information related to their particular diagnosis, cure or treatment of a condition or disorder.
The current version of DisGeNET (v7.0) contains 1,134,942 gene-disease associations (GDAs), between 21,671 genes and 30,170 diseases, disorders, traits, and clinical or abnormal human phenotypes, and 369,554 variant-disease associations (VDAs), between 194,515 variants and 14,155 diseases, traits, and phenotypes.